Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Alicia Lopez & Jose Rey. (2019) Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice. Neuropsychiatric Disease and Treatment 15, pages 449-456.
Read now
Read now
Xue Song, Antoine C. El Khoury, Matthew Brouillette, David Smith & Kruti Joshi. (2019) Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. Journal of Medical Economics 22:11, pages 1105-1112.
Read now
Read now
Antoine C. El Khoury, Dominic Pilon, Laura Morrison, Nina Shak, Maude Vermette-Laforme, Tony B. Amos, Edward Kim & Patrick Lefebvre. (2019) The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. Current Medical Research and Opinion 35:3, pages 395-405.
Read now
Read now
Lora Beebe, Kathlene D. Smith & Lauren Michelle Oppizzi. (2018) Telephone Intervention–Problem Solving (TIPS) for Schizophrenia Spectrum Disorders: Responses of Stable Outpatients Over Nine Months. Issues in Mental Health Nursing 39:7, pages 561-567.
Read now
Read now
Mallik Greene, Tingjian Yan, Eunice Chang, Ann Hartry, Maëlys Touya & Michael S. Broder. (2018) Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. Journal of Medical Economics 21:2, pages 127-134.
Read now
Read now
Kruti Joshi, Marie-Hélène Lafeuille, Brianne Brown, Willy Wynant, Bruno Emond, Patrick Lefebvre & Neeta Tandon. (2017) Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting. Current Medical Research and Opinion 33:10, pages 1763-1772.
Read now
Read now
Articles from other publishers (22)
John M. Kane, Anna Chen, Sangtaeck Lim, Marko A. Mychaskiw, Marc Tian, Yitong Wang, Mark Suett & Jose M. Rubio. (2023) Early versus late administration of long-acting injectable antipsychotic agents among patients with newly diagnosed schizophrenia: an analysis of a commercial claims database. International Clinical Psychopharmacology 38:4, pages 240-248.
Crossref
Crossref
Laura MorrisonDee LinCarmela BensonIsabelle GhelerterMaude Vermette-LaformePatrick LefebvreDominic Pilon. (2023) Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate. Journal of Managed Care & Specialty Pharmacy 29:2, pages 161-171.
Crossref
Crossref
Carey Pike & Linda-Gail Bekker. (2023) Interrogating the promise of long-acting HIV pre-exposure prophylaxis. Trends in Molecular Medicine 29:2, pages 93-98.
Crossref
Crossref
Ana Aliana Miron, Paula Simina Petric, Andreea Teodorescu, Petru Ifteni, Gabriela Chele & Andreea Silvana Szalontay. (2023) Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study. Brain Sciences 13:2, pages 173.
Crossref
Crossref
Itay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, Michael Lamson, Eran Harary, Ofer Spiegelstein, Attila Kalmanczhelyi, Ryan Tiver, Pippa Loupe, Micha Levi & Anna Elgart. (2022) Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone. Clinical Pharmacology in Drug Development 11:7, pages 865-877.
Crossref
Crossref
Charmi Patel, Ahong Huang, Li Wang, Yoshita Paliwal & Kruti Joshi. (2022) Patient Journey of Veterans with Schizophrenia: An Analysis of Treatment Patterns, Healthcare Resource Utilization and Costs. Advances in Therapy 39:3, pages 1199-1214.
Crossref
Crossref
Péter Takács, Péter Kunovszki, Valeria Timtschenko, László Fehér, Tamás Balázs, Ramóna Hegyi, Pál Czobor & István Bitter. (2022) Comparative Effectiveness of Second Generation Long-acting Injectable Antipsychotics Based on Nationwide Database Research in Hungary: An Update. Schizophrenia Bulletin Open 3:1.
Crossref
Crossref
Linda‐Gail Bekker, Carey Pike & Sharon L. Hillier. (2022) HIV prevention: better choice for better coverage. Journal of the International AIDS Society 25:1.
Crossref
Crossref
Enrico Capuzzi, Alessandro Ceresa, Alice Caldiroli, Cecilia M. Esposito, Paolo Ossola & Massimiliano Buoli. (2021) The Relation between the Plasma Concentrations of Long-Acting Atypical Antipsychotics and Clinical Effectiveness in Patients Affected by Schizophrenia or Schizoaffective Disorder: A Comprehensive Overview. Current Pharmaceutical Design 27:39, pages 4070-4077.
Crossref
Crossref
John Lauriello, Peter J. Weiden, Carole D. Gleeson, Ankit Shah, Luke Boulanger, Krutika Jariwala-Parikh, Elizabeth Hedgeman & Amy K. O’Sullivan. (2021) Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia. CNS Drugs 35:10, pages 1123-1135.
Crossref
Crossref
Dee Lin, Philippe Thompson-Leduc, Isabelle Ghelerter, Ha Nguyen, Marie-Hélène Lafeuille, Carmela Benson, Panagiotis Mavros & Patrick Lefebvre. (2021) Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. CNS Drugs 35:5, pages 469-481.
Crossref
Crossref
Xiaobing Guo, Hongye Yu & Hu Wang. (2021) Antipsychotic patterns in outpatients with schizophrenia in China. Medicine 100:32, pages e26912.
Crossref
Crossref
Jörg Mahlich, Kerstin Olbrich, Adrian Wilk, Antonie Wimmer & Claus Wolff-Menzler. (2020) Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics. Clinical Drug Investigation 41:1, pages 99-113.
Crossref
Crossref
Valeria Latorre, Apostolos Papazacharias, Maria Lorusso, Gaetano Nappi, Paola Clemente, Antonia Spinelli, Giovanni Carrieri, Enrico D’Ambrosio, Michele Gattullo, Antonio Emmanuele Uva & Domenico Semisa. (2020) Improving the “real life” management of schizophrenia spectrum disorders by LAI antipsychotics: A one-year mirror-image retrospective study in community mental health services. PLOS ONE 15:3, pages e0230051.
Crossref
Crossref
Antoine C. El KhouryDominic PilonLaura MorrisonNina Shak, Amanda LlanezaEdward KimPatrick Lefebvre. (2020) Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia. Journal of Managed Care & Specialty Pharmacy 26:2, pages 176-185.
Crossref
Crossref
Charmi Patel, Antoine El Khoury, Ahong Huang, Li Wang, Onur Baser & Kruti Joshi. (2019) Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Advances in Therapy 36:10, pages 2941-2953.
Crossref
Crossref
Christine Lin, Rebecca Strauss, Jenny Hong, Jeffrey G. Hamper, Emma Sew Hoy, Ann A. Lazar & Lisa Kroon. (2019) Impact of a pharmacist‐administered long‐acting injectable antipsychotic service in a supermarket‐based community pharmacy on medication adherence. JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY 2:4, pages 343-348.
Crossref
Crossref
Janet Sultana, Isabel Hurtado, Daniel Bejarano-Quisoboni, Francesco Giorgianni, Krista F. Huybrechts, Zhigang Lu, Elisabetta Patorno, Gabriel Sanfélix-Gimeno, Daniele Ugo Tari & Gianluca Trifirò. (2019) Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. European Journal of Clinical Pharmacology 75:7, pages 1005-1015.
Crossref
Crossref
Ankit Shah, Lin Xie, Furaha Kariburyo, Qisu Zhang & Mugdha Gore. (2018) Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics. Advances in Therapy 35:11, pages 1994-2014.
Crossref
Crossref
C. Dondé, P. Vignaud, E. Poulet, J. Brunelin & F. Haesebaert. (2018) Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines. Acta Psychiatrica Scandinavica 138:4, pages 289-299.
Crossref
Crossref
Giovanni Ostuzzi, Maria Angela Mazzi, Samira Terlizzi, Federico Bertolini, Andrea Aguglia, Francesco Bartoli, Paola Bortolaso, Camilla Callegari, Mariarita Caroleo, Giuseppe Carrà, Mariangela Corbo, Armando D’Agostino, Chiara Gastaldon, Claudio Lucii, Fabio Magliocco, Giovanni Martinotti, Michela Nosé, Edoardo Giuseppe Ostinelli, Davide Papola, Marco Piero Piccinelli, Alberto Piccoli, Marianna Purgato, Tommaso Tabacchi, Giulia Turrini, Mirella Ruggeri & Corrado Barbui. (2018) Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. PLOS ONE 13:8, pages e0201371.
Crossref
Crossref
Yueren Zhao, Tetsuya Tanioka, Yuko Yasuhara, Kensaku Takase, Soji Tsuboi, Kiyoshi Fujita, Rozzano C. Locsin & Nakao Iwata. (2017) Effects of Depth of Needle Insertion with Risperidone Long-Acting Injectable in Persons with Schizophrenia: A Randomized Double-Blind Study. Open Journal of Psychiatry 07:04, pages 374-385.
Crossref
Crossref